Who developed Memoblast and when was it first introduced or patented?

1. What the record actually shows: Mesoblast, not “Memoblast”

Search results and company filings in the available reporting repeatedly reference Mesoblast Limited as the company behind mesenchymal precursor cell technology and related patents ^{[1] [2]}. I could not find any mention of a distinct product, company, or therapy named “Memoblast” in the supplied sources; therefore, available sources do not mention “Memoblast” as a developer or patented product (not found in current reporting).

2. Who developed the mesenchymal precursor / stromal cell technology

The developer named throughout the supplied material is Mesoblast Limited (and related Mesoblast entities). Mesoblast’s public materials describe proprietary mesenchymal-lineage cell technologies — Mesenchymal Precursor Cells (MPCs) and Mesenchymal Stromal/Stem Cells (MSCs) — and attribute inventions and patent assignments to Mesoblast and named inventors on patents assigned to Mesoblast entities ^{[1] [4] [5]}.

3. Key patent milestones cited in company reporting

Mesoblast announced grants of core patents covering its MPC technology in early 2013 — a company release dated 7 February 2013 said Mesoblast had been granted three key new patents by the USPTO and Chinese authorities that underpin its MPC platform ^[2]. Wikipedia-style reporting also flags a February 10, 2015 U.S. patent grant covering Mesoblast’s MPC technology for degenerated intervertebral discs ^[3]. Mesoblast’s corporate overview emphasizes an extensive IP estate of roughly 1,000 patents and applications with protection stretching through 2040 ^[1].

4. Examples of named inventors and patent filings

Patent listings associated with Mesoblast entities show named inventors such as Silviu Itescu, Lee Golden, Ravi Krishnan and Peter Ghosh on patents assigned to Mesoblast or Mesoblast International Sàrl; recent patent dates appear as late as 2023 in the Justia patent summaries ^{[5] [4]}. Those records support that Mesoblast and its founders/teams are active patent filers in this technology area ^{[5] [4]}.

5. Ambiguities and limitations in the available sources

The supplied documents do not mention any product spelled “Memoblast,” nor do they identify a specific first-introduction or registration event tied to that name; thus, I cannot verify who “developed Memoblast” or when it was introduced or patented from the available material (not found in current reporting). The materials focus on Mesoblast’s MPC/MSCs broadly, press releases about patent grants in 2013 and 2015, and statements about an overall patent portfolio ^{[2] [3] [1]}.

6. Possible explanations and how to proceed

There are a few possibilities consistent with the supplied reporting: (a) “Memoblast” may be a misremembering or typographical error for “Mesoblast”; (b) “Memoblast” could be a separate, unreferenced commercial supplement or trademark not covered in these sources; or (c) it may be an informal name used outside the documents provided. Because the provided sources document Mesoblast’s MPC/MSCs and patent activity (including grants in February 2013 and a 2015 U.S. patent reference) but not “Memoblast,” the most prudent next step is to search external databases (trademark registries, USPTO patent search, company product lists, or news archives) for the exact term “Memoblast” if you want definitive origin/filing dates ^{[2] [3] [1]}.

7. Bottom line for your question

Based on the supplied sources, Mesoblast is the party associated with the mesenchymal precursor/stromal cell technologies and specific patent grants (notably announced patent grants in February 2013 and cited U.S. patent grant references in 2015), and Mesoblast claims an IP portfolio of about 1,000 patents and applications with coverage through 2040 ^{[2] [3] [1]}. Available sources do not mention “Memoblast,” so I cannot assert who developed or patented “Memoblast” or when it was first introduced from the current reporting (not found in current reporting).